Active, not recruitingPhase 3NCT05367960

An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

Studying Fragile X syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tetra Discovery Partners
Principal Investigator
Elizabeth Berry-Kravis, MD
Rush University Medical Center
Intervention
Zatolmilast/ BPN14770(drug)
Enrollment
314 enrolled
Eligibility
9-45 years · MALE
Timeline
20222027

Study locations (17)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05367960 on ClinicalTrials.gov

Other trials for Fragile X syndrome

Additional recruiting or active studies for the same condition.

See all trials for Fragile X syndrome

← Back to all trials